½ÃÀ庸°í¼­
»óǰÄÚµå
1493429

ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Á¦Ç°º°, µµÀÔ ¸ðµ¨º°, ÃÖÁ¾ »ç¿ëº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2024-2030³â)

Medical Scheduling Software Market Size, Share & Trends Analysis Report By Product (Patient, Care Provider), By Deployment Model (Cloud-based, On-premise), By End Use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 7¾ï 4,987¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2030³â 13.3%ÀÇ CAGR·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº ¼ÒÁøÀ» ÁÙÀ̱â À§ÇØ ´õ ³ªÀº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ÃÖ±Ù ¼ö³â°£ ÀÇ·á Àü¹®°¡ ºÎÁ·Àº ÀÇ»ç¿Í °£È£»çÀÇ ¼ÒÁøÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ³ëµ¿ Åë°è±¹Àº 2020-2030³â 275,000¸í ÀÌ»óÀÇ °£È£»ç°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹°£È£ÇùȸÇùÀÇȸ(NCSBN)´Â ÃÖ±Ù 2020³â ÀÌÈÄ 10¸¸ ¸íÀÇ Á¤±ÔÁ÷ °£È£»ç°¡ ÀÌÁ÷ÇÒ °ÍÀ̶ó°í º¸°íÇß½À´Ï´Ù.

¶ÇÇÑ ½ÃÀå ÁÖ¿ä ¾÷üµéÀÇ Àü·«Àû ±¸»ó Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» º¸¿ÏÇÒ °ÍÀ¸·Î º¸À̸ç, ȯÀÚ °æÇèÀ» °³¼±Çϱâ À§ÇÑ Ç÷§ÆûÀÎ NexHealth´Â ÃÖ±Ù ½Ã¸®Áî C¿¡¼­ 1¾ï 2,500¸¸ ´Þ·¯ÀÇ ÅõÀÚ¸¦ À¯Ä¡Çß½À´Ï´Ù. ±× °á°ú, ½Å±Ô ±â¾÷ÀÇ Æò°¡¾×Àº 10¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ³Ø½ºÇコ(NexHealth)´Â ÀÇ»ç, Ä¡°úÀÇ»ç µî ÀÇ·á Àü¹®°¡µéÀÇ ½ºÄÉÁÙ¸µ, ¸Þ½Ã¡ µîÀÇ ¾÷¹«¸¦ °£¼ÒÈ­ÇÏ´Â µ¿½Ã¿¡ °ü¸® ÇÁ·Î¼¼½º¸¦ ÀÚµ¿È­ÇÏ¿© ȯÀÚ¿¡°Ô ¹ø°Å·Î¿ò ¾ø´Â µðÁöÅÐ °æÇèÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÀÎÅÍ³Ý »ç¿ëÀÚ Áõ°¡¿Í Àα¸ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î Internet World Stats¿¡ µû¸£¸é 2022³â 7¿ù ÇöÀç À¯·´ÀÇ ÀÎÅÍ³Ý »ç¿ëÀÚ´Â 54¾ï 7,590¸¸ ¸í¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ȯÀÚ ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ºÐ¾ß°¡ 2023³â ½ÃÀåÀ» Àå¾ÇÇϸç 41.83%ÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸ð¹ÙÀÏ »ç¿ë Áõ°¡¿Í µðÁöÅÐ ±â¼úÀÇ ¼ºÀåÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¿ä¾çº¸È£»ç ½ºÄÉÁÙ¸µ ºÎ¹®Àº ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼ºÁúȯÀÇ È®»êÀ¸·Î ÀÎÇÑ È¯ÀÚ Áø·áÀÇ ±ÞÁõÀº ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î CDC º¸°í¼­¿¡ µû¸£¸é ¹Ì±¹ÀÎ 10¸í Áß 6¸íÀÌ ¾Ï, ½ÉÀ庴, ³úÁ¹Áß, ´ç´¢º´ µî Àû¾îµµ ÇÑ °¡Áö ÀÌ»óÀÇ ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù.
  • 2023³â¿¡´Â Ŭ¶ó¿ìµå ±â¹Ý ºÎ¹®ÀÌ ½ÃÀåÀ» Àå¾ÇÇÏ°í °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀÔ´Ï´Ù. ¸ð¹ÙÀÏ »ç¿ëÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ȯÀÚ Áß½É Ä¡·á¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁ® ½ÃÀå ¼ºÀåÀ» º¸¿ÏÇÒ °ÍÀÔ´Ï´Ù.
  • 2023³â¿¡´Â º´¿ø ºÎ¹®ÀÌ ½ÃÀåÀ» Àå¾ÇÇÏ¿© °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ Ã¤Åà Áõ°¡¿Í ÇÔ²² Á¦Ç° Ãâ½Ã ¹× ½ÃÀå °³Ã´ÀÌ ±ÞÁõÇϸ鼭 ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â 2023³â ÁÖ¿ä Áö¿ªÀ¸·Î ºÎ»óÇÏ¿© 42.78%ÀÇ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç¿Í È®¸³µÈ ÀÇ·á ÀÎÇÁ¶ó°¡ ½ÃÀå ¼ºÀåÀ» º¸¿ÏÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - PorterÀÇ »ê¾÷ ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¦Ç° ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • Á¦Ç°º° : ¼¼°èÀÇ ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
  • ȯÀÚ ½ºÄÉÁÙ¸µ
  • Äɾî Á¦°øÀÚ ½ºÄÉÁÙ¸µ
  • ±âŸ

Á¦5Àå ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : µµÀÔ ¸ðµ¨ ÃßÁ¤¡¤µ¿Ç⠺м®

  • µµÀÔ ¸ðµ¨ÀÇ ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • µµÀÔ ¸ðµ¨º° : ¼¼°èÀÇ ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ Àü¸Á
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
  • Ŭ¶ó¿ìµå ±â¹Ý
  • ¿ÂÇÁ·¹¹Ì½º

Á¦6Àå ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ÃÖÁ¾ ¿ëµµº° : ¼¼°èÀÇ ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
  • º´¿ø
  • Ŭ¸®´Ð
  • ±âŸ

Á¦7Àå ÀÇ·á ½ºÄÉÁÙ¸µ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°è Áö¿ª ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷/°æÀï ºÐ·ù
  • ±â¾÷ÀÇ ½ÃÀå ÇöȲ ºÐ¼®
  • ±â¾÷ °³¿ä
    • Kareo
    • Oracle
    • NXGN Management, LLC.
    • American Medical Software
    • Q-nomy Inc.
    • Biosoftworld Medical Software
    • Caspio
    • SuperSaaS
    • PatientStudio
    • AdvancedMD, Inc.
    • TIMIFY
    • Sign In Solutions Inc
    • Kyruus
  • Àü·« ¸ÅÇÎ
KSA 24.06.21

Medical Scheduling Software Market Growth & Trends:

The global medical scheduling software market size is anticipated to reach USD 749.87 million by 2030 and is expected to grow at a CAGR of 13.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market's growth can be attributed to the growing demand for better provider scheduling software to reduce burnout. In recent years, a shortage of healthcare professionals has led to burnout among physicians and nurses. For instance, the U.S. Bureau of Labor Statistics has projected that over 275,000 nurses will be required between 2020 and 2030. In addition, the National Council of State Boards of Nursing (NCSBN) has recently reported that 100,000 registered nurses have left the profession since 2020.

In addition, increasing strategic initiatives by key market players will supplement market growth. NexHealth, a platform that aims to enhance patient experience, has recently raised USD 125 million in series C funding. As a result, the startup's valuation has now reached USD 1 billion. NexHealth provides a hassle-free digital experience to patients by streamlining tasks such as scheduling and messaging while simultaneously automating administrative processes for healthcare professionals such as doctors and dentists. Furthermore, increasing internet users and a growing population will escalate market growth. For instance, as per the Internet World Stats, as of July 2022, there were 5,475.9 million Internet users in Europe.

Medical Scheduling Software Market Report Highlights:

  • The patient scheduling software segment dominated the market in 2023, holding the largest share of 41.83%. The increasing mobile usage coupled with growing digital technologies are anticipated to boost market growth
  • The care provider scheduling segment shows the fastest growth during the forecast period. Surge in several patient visits due to the increasing prevalence of chronic disease is expected to impact market growth. For instance, as per the CDC report, Six out of ten Americans are living with at least one chronic disease, such as cancer, heart disease, stroke, or diabetes
  • In 2023, cloud-based segment dominated the market, representing the largest. Increasing emphasis on patient-centric care along with growing mobile phone users will supplement market growth
  • Hospitals segment dominated the market in 2023, representing the largest share. Surge in product launches and developments, along with the rising adoption of cloud computing, are anticipated to spur market growth
  • North America emerged as the leading region in 2023, holding the largest share of 42.78%. Presence of key market players, along with a well-established healthcare infrastructure, will supplement market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.1.1. Product Type
    • 1.1.2. Deployment Model
    • 1.1.3. End-use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Type Outlook
    • 2.2.2. Deployment Model Outlook
    • 2.2.3. End-use Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Medical Scheduling Software Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing demand for software to efficiently manage and optimize workflow
      • 3.2.1.2. Rising adoption of patient-centric approach
      • 3.2.1.3. Increasing prevalence of chronic diseases
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Security and privacy issues
      • 3.2.2.2. Resistance to change
  • 3.3. Medical Scheduling Software Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Medical Scheduling Software Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Medical Scheduling Software Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 4.4.1. Patient Scheduling
      • 4.4.1.1. Patient Scheduling Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Care Provider Scheduling
      • 4.4.2.1. Care Provider Scheduling Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Other Products
      • 4.4.3.1. Other Products Market Estimates and Forecasts 2018 - 2030 (USD Million)

Chapter 5. Medical Scheduling Software Market: Deployment Model Estimates & Trend Analysis

  • 5.1. Deployment Model Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Medical Scheduling Software Market by Deployment Model Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 5.4.1. Cloud-Based
      • 5.4.1.1. Cloud-Based Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 5.4.2. On-Premise
      • 5.4.2.1. On-Premise Market Estimates and Forecasts 2018 - 2030 (USD Million)

Chapter 6. Medical Scheduling Software Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Medical Scheduling Software Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 6.4.1. Hospitals
      • 6.4.1.1. Hospitals Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.4.2. Clinics
      • 6.4.2.1. Clinics Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.4.3. Other End Use
      • 6.4.3.1. Other End Use Market Estimates and Forecasts 2018 - 2030 (USD Million)

Chapter 7. Medical Scheduling Software Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 - 2030
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.6. Denmark
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.8. Norway
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Competitive scenario
      • 7.6.8.3. Regulatory framework
      • 7.6.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. India market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.4. South Korea
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Competitive scenario
      • 7.7.6.3. Regulatory framework
      • 7.7.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Competitive scenario
      • 7.9.1.3. Regulatory framework
      • 7.9.1.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million) (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Competitive scenario
      • 7.9.2.3. Regulatory framework
      • 7.9.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Competitive scenario
      • 7.9.3.3. Regulatory framework
      • 7.9.3.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Competitive scenario
      • 7.9.4.3. Regulatory framework
      • 7.9.4.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Company Market Position Analysis
  • 8.3. Company Profile
    • 8.3.1. Kareo
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Oracle
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. NXGN Management, LLC.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. American Medical Software
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Q-nomy Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Biosoftworld Medical Software
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Caspio
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. SuperSaaS
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. PatientStudio
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AdvancedMD, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. TIMIFY
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Sign In Solutions Inc
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Kyruus
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
  • 8.4. Strategy Mapping
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦